Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Capital Employed (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Return on Capital Employed for 15 consecutive years, with 0.66% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 52.0% to 0.66% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.66%, a 52.0% decrease, with the full-year FY2025 number at 0.53%, down 39.0% from a year prior.
  • Return on Capital Employed was 0.66% for Q4 2025 at Myriad Genetics, up from 0.76% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.12% in Q3 2022 to a low of 0.76% in Q3 2025.
  • A 5-year average of 0.27% and a median of 0.19% in 2021 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: rose 12bps in 2024, then tumbled -52bps in 2025.
  • Myriad Genetics' Return on Capital Employed stood at 0.17% in 2021, then rose by 22bps to 0.13% in 2022, then plummeted by -97bps to 0.26% in 2023, then soared by 47bps to 0.14% in 2024, then crashed by -378bps to 0.66% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Return on Capital Employed are 0.66% (Q4 2025), 0.76% (Q3 2025), and 0.65% (Q2 2025).